LYRA · As filed with the SEC
Lyra Therapeutics income statement, by fiscal year
The statement as Lyra Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Loss · USD, except per-share amounts
| USD, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Collaboration revenue | 398,000 | 1,534,000 | 1,558,000 | 1,363,000 | 285,000 | — | — |
| Operating expenses: | |||||||
| Research and development | 18,411,000 | 43,766,000 | 48,029,000 | 38,797,000 | 29,694,000 | 12,522,000 | 12,032,000 |
| General and administrative | 11,540,000 | 18,501,000 | 19,057,000 | 17,556,000 | 14,206,000 | 9,687,000 | 4,487,000 |
| Impairment of property and equipment | — | 1,883,000 | 1,592,000 | 1,316,000 | — | — | — |
| Impairment of right-of-use assets | — | 22,836,000 | — | — | — | — | — |
| Restructuring and other related charges | 1,469,000 | 10,896,000 | — | — | — | — | — |
| Total operating expenses | 31,420,000 | 97,882,000 | 68,678,000 | 57,669,000 | 43,900,000 | 22,209,000 | 16,519,000 |
| Loss from operations | (31,022,000) | (96,348,000) | (67,120,000) | (56,306,000) | (43,615,000) | (22,209,000) | (16,519,000) |
| Other income: | |||||||
| Interest income | 1,133,000 | 2,952,000 | 4,499,000 | 1,041,000 | 102,000 | 82,000 | 213,000 |
| Other Income | 981,000 | — | — | — | — | — | — |
| Total other income | 2,114,000 | 2,952,000 | 4,499,000 | 1,041,000 | 102,000 | 82,000 | 213,000 |
| Loss before income tax expense | (28,908,000) | (93,396,000) | (62,621,000) | (55,265,000) | — | — | — |
| Income tax expense | (11,000) | (39,000) | (59,000) | (13,000) | — | — | — |
| Net loss | (28,919,000) | (93,435,000) | (62,680,000) | (55,278,000) | (43,513,000) | (22,127,000) | (16,306,000) |
| Other comprehensive loss: | |||||||
| Unrealized holding income (loss) on short-term investments, net of tax | — | (33,000) | 23,000 | 10,000 | — | — | — |
| Comprehensive loss | (28,919,000) | (93,468,000) | (62,657,000) | (55,268,000) | (43,513,000) | (22,127,000) | (16,306,000) |
| Net loss per share attributable to common stockholders—basic and diluted | — | — | — | — | (3.35) | (2.59) | (82.23) |
| Weighted-average common shares outstanding—basic and diluted | — | — | — | — | 12,986,101 | 8,590,205 | 202,093 |
| Net loss per share attributable to common stockholders- basic | (18.62) | (1.43) | (1.26) | (1.83) | — | — | — |
| Net loss per share attributable to common stockholders-diluted | (18.62) | (1.43) | (1.26) | (1.83) | — | — | — |
| Weighted-average common shares outstanding-basic | 1,553,473 | 65,113,859 | 49,804,283 | 30,235,689 | — | — | — |
| Weighted-average common shares outstanding-diluted | 1,553,473 | 65,113,859 | 49,804,283 | 30,235,689 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.